Last reviewed · How we verify

NCT07521735

NEXT GEN - PHILIPS OPTIMUS

Recruiting now Last updated 13 April 2026
What this trial tests

trial testing Philips MR400 Pro MRI Patient Monitor in Pulse Oximetry in 36 participants. Currently enrolling.

Timeline
9 March 2026
Primary endpoint
3 April 2026
3 April 2026

Quick facts

Lead sponsorPhilips Clinical & Medical Affairs Global
StatusRecruiting now
Study typeOBSERVATIONAL
Enrollment36
Start date9 March 2026
Primary completion3 April 2026
Estimated completion3 April 2026
Sites1 location across United States

Drugs / interventions tested

Conditions studied

Sponsor

Philips Clinical & Medical Affairs Global — full company profile →

Who can join

Adults 18 to 50, any sex, with Pulse Oximetry. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this clinical study is to validate the SpO2 accuracy performance of the sponsor's SpO2 sensors over the range of 70-100% SaO2 during non-motion conditions assessed by CO-Oximetry.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other Philips Clinical & Medical Affairs Global trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07521735.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing